Current Neuro-Oncology

Volume 27 Number 36
31 December 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 36, 31 December

Campino GA, Shrot S, Constantini S, Roth J, Toren A, Lurye M, Yalon-Oren M.
Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation.
Childs Nerv Syst. 2025 Dec 21;41(1):429. doi: 10.1007/s00381-025-07084-w. PMID: 41423525. Case report. ˍ

van den Bent MJ, Ghisai SA, Wick W, Sanson M, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Tabouret E, Gill S, Griffin M, Taal W, Rudà R, Weller M, McBain C, Reijneveld JC, Enting RH, Tran S, Lesimple T, Kocher M, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Hoogstrate Y, Nuyens S, Golfinopoulos V, Tesileanu CMS, Gorlia T, French P, Baumert BG.
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
Lancet Oncol. 2025 Dec 22;27(1):45-56. doi: 10.1016/S1470-2045(25)00614-X. PMID: 41449147. Interventional study˰ ˍ

Evers Smith JW, Alzate JD, Power L, Wei W, Chao ST, Siddiq M, Prayson R, Barnett GH, Mohammadi AM, Grabowski MM, Suh JH, Murphy ES, Yu JS, Balagamwala E, Neyman G, Stevens GHJ, Peereboom D, Dhawan A, Angelov L.
The impact of the molecular and genetic properties of glioblastoma on patient outcomes following stereotactic radiosurgery at recurrence.
J Neurooncol. 2025 Dec 23;176(2):132. doi: 10.1007/s11060-025-05367-5. PMID: 41432822. Observational study˰ ˍ

Arcos-Montoya D, García-López P, Wegman-Ostrosky T, Camacho-Arroyo I, Valdés-Rives SA, Bello-Alvarez C, Manjarrez-Marmolejo J, De La Fuente-Granada M, Ordaz-Ramos A, Ávila-González D, Díaz NF, Guadarrama-Rangel CF, Navarrete AMB, Aboud O, Cantú-de-León DF, Cacho-Díaz B, González-Arenas A.
Assessing progesterone receptor modulation in glioblastoma: from in vitro and animal model to a human pilot protocol.
Cancer Biol Ther. 2025 Dec 24;27(1):2603095. doi: 10.1080/15384047.2025.2603095. PMID: 41439468. Interventional study. ˍ

Nåhls NS, Anttonen A, Kitti P, Leskelä RL, Akrén O, Saarto T, Carpén T.
Early palliative care decision in patients with primary brain tumor reduces emergency department visits and hospitalization at the end of life.
J Neurooncol. 2025 Dec 24;176(2):137. doi: 10.1007/s11060-025-05377-3. PMID: 41442055. Observational study. ˍ

Ji M, Tian D, Qi Q, Zhao L, Tan P, Lin P, Li Q, Wu J, Lai Y, Cheng Y, Yang H, Ma H.
Analytical Insights into the Epidemiology of Glioma and Treatment Modalities.
World Neurosurg. 2025 Dec 26:124757. doi: 10.1016/j.wneu.2025.124757. PMID: 41456753. Observational study. ˍ

Suryadevara CM, Donaldson H, Khan HA, Groff KJ, Kim CD, Dogra S, Gautreaux J, Roberts LG, Young MG, Snuderl M, Zagzag D, William CM, McFaline-Figueroa JR, Pilar Guillermo Prieto Eibl MD, Cordova CA, Kurz S, Barbaro M, Placantonakis DG.
Neoadjuvant PD1 blockade with laser interstitial thermal therapy for recurrent high-grade glioma.
J Clin Neurosci. 2025 Dec 27;145:111823. doi: 10.1016/j.jocn.2025.111823. PMID: 41456377. Observational study. ˍ

Keric N, Krenzlin H, Lange F, Dauth A, Freyschlag CF, Schnellg O, Misch M, von der Brelie C, Gempt J, Krigers A, Wagner A, Mielke D, Sommer C, Brockmann MA, Meyer B, Rohde V, Vajkoczy P, Beck J, Thomé C, Ringel F.
Treatment differences in IDH-wildtype glioma - the impact of surgery and adjuvant therapy.
J Neurooncol. 2025 Dec 29;176(2):145. doi: 10.1007/s11060-025-05368-4. PMID: 41466163. Observational study. ˍ

Mueller T, Vasella F, Velz J, Voglis S, Akeret K, Padevit L, Schubert M, Weller J, Brüningk S, Rushing E, Sarnthein J, Gramatzki D, Häni L, Raabe A, Zeitlberger AM, Bozinov O, Le Rhun E, Weller M, Regli L, Neidert MC.
Conditional survival in glioblastoma: The evolution of prognostic factors over time.
Int J Cancer. 2025 Dec 30. doi: 10.1002/ijc.70285. PMID: 41472359. Observational study. ˍ

Uthamacumaran A, Horth C, Bareke E, Gravel M, Majewski J.
Cellular reprogramming of H3K27M pediatric high-grade glioma to neuron-like state.
Acta Neuropathol Commun. 2025 Dec 30. doi: 10.1186/s40478-025-02185-8. PMID: 41469740. Laboratory investigation. ˍ

Zhang R, Zhang C, Jiang G, Ren Y, Zhang Y, Niu X.
Clinical Features and Prognostic Indicators for Brainstem Ependymomas : A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
J Korean Neurosurg Soc. 2025 Dec 30. doi: 10.3340/jkns.2025.0117. PMID: 41461149. Observational study. ˍ

Phan P, Stapleton SL, Riggins GJ, Koldobskiy MA, Raabe E, Cohen KJ.
Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors.
Neurooncol Pract. 2025 Jun 7;12(6):1092-1098. doi: 10.1093/nop/npaf060. PMID: 41458919. Interventional study˰ ˍ

Ioannou M, Mehta S, Devkota A, Bagley SJ, Ozer BH, Romo CG, Welch MR, Justin JT, Holdhoff M, Schreck KC.
Clinical experience with tovorafenib in adults with treatment-refractory high- and low-grade gliomas.
Neurooncol Pract. 2025 Jul 18;12(6):1051-1057. doi: 10.1093/nop/npaf068. PMID: 41458920. Observational study˰ ˍ

Geoerger B, Moreno L, Bouffet E, Upadhyaya SA, André N, Aerts I, Plant-Fox AS, Roughton M, Russo M, Hargrave D.
Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study.
Neurooncol Pract. 2025 Aug 16;12(6):1099-1111. doi: 10.1093/nop/npaf061. PMID: 41458923. Interventional study. ˍ

Chen CG, Rameh V, Rosenberg T, Yeo KK, Chi S, Wright KD, Baird LC, Filbin MG, Fehnel KP, Abdullaev Z, Aldape KD, Lidov HG, Alexandrescu S.
H3K27M- and BRAF V600E-Altered gliomas and glioneuronal tumors-clinico-pathologic and radiologic perspective in a cohort treated with targeted therapy.
Neurooncol Adv. 2025 Sep 8;7(1):vdaf197. doi: 10.1093/noajnl/vdaf197. PMID: 41473746. Observational study. ˍ

Zhang W, Li Y, Lin L, Wang Y, Guan Y.
A Causal Relationship Between the Lipidome and Central Nervous System Tumors.
World Neurosurg. 2025 Oct 24;204:124590. doi: 10.1016/j.wneu.2025.124590. PMID: 41429738. Laboratory investigation. ˍ

Kim W, Park JS, Song JH, Yoo H, Park K, Kim HJ, Shin DW, Lee SU, Ahn S, Ha S, Yi J, Cho K, Seo HJ, Lim HS, Yee GT.
Boron Neutron Capture Therapy in Recurrent High-Grade Gliomas: Safety, Efficacy, and Pharmacokinetics From a Multicenter, Dose-Escalation Phase 1 Trial.
Adv Radiat Oncol. 2025 Oct 30;11(1):101947. doi: 10.1016/j.adro.2025.101947. PMID: 41438484. Interventional study. ˍ

Mikic N, Lukacova S, Skjøth-Rasmussen J, Poulsen FR, Hauerberg J, Laursen RJ, Ettrup KS, Møller S, Haslund CA, Dahlrot RH, Cortnum SOS, Sindby AK, Von Oettingen G, Valentin JB, Solheim O, Solheim TS, Sørensen JCH, Wong ET, Korshøj AR.
Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial.
Neurooncol Adv. 2025 Nov 20;7(1):vdaf245. doi: 10.1093/noajnl/vdaf245. PMID: 41473750. Interventional study. ˍ

Ruggiero A, Talloa D, Romano A, Attinà G, Mastrangelo S, Maurizi P, Verdolotti T, Tamburrini G, Chiesa S, di Bonaventura R, Mattogno PP, Olivi A, Albanese A.
Outcomes and Toxicity of Adult Medulloblastoma Treated with Pediatric Multimodal Protocols: A Single-Institution Experience.
Oncol Res. 2025 Nov 27;33(12):3855-3867. doi: 10.32604/or.2025.067948. PMID: 41425728. Observational study. ˍ

Shibuya N, Higa N, Akahane T, Yonezawa H, Kirishima M, Tanimoto A, Hanaya R.
A Case of Multicentric Isocitrate Dehydrogenase-Wildtype Glioblastoma With Divergent Clonal Evolution.
Cureus. 2025 Nov 29;17(11):e98066. doi: 10.7759/cureus.98066. PMID: 41473634. Case report. ˍ

Ge J, Li C, Xue F, Zhao C, Kong C, Qi S, Duan Q, Zhang Q, Zhang J.
Alterations of the tumor microenvironment (TME) by exploratory gene expression analysis in recurrent glioblastoma following apatinib in combination with temozolomide.
Biochem Biophys Rep. 2025 Dec 1;45:102364. doi: 10.1016/j.bbrep.2025.102364. PMID: 41438689. Observational study. ˍ

Phillips NS, Zhang S, Baedke J, Ji Q, Sabin ND, Ness KK, Hudson MM, Yasui Y, Mahapatra S, Kumbaji M, Tatevossian RG, Scoggins MA, Williams AM, Krull KR.
Accelerated Brain Aging, Atherogenicity, and Neurocognition in Adult Survivors of Childhood Cancer.
JAMA Netw Open. 2025 Dec 1;8(12):e2551865. doi: 10.1001/jamanetworkopen.2025.51865. PMID: 41468012. Observational study. ˍ

Chen J, Conyngham S, Bayly A, McMaster J, Trang J.
A rare case of adult H3 K27-altered diffuse midline glioma with multifocal cerebrospinal fluid disseminated disease.
Radiol Case Rep. 2025 Dec 4;21(2):897-902. doi: 10.1016/j.radcr.2025.11.042. PMID: 41438665. Case report. ˍ

Grosu AL, Weber WA, Graf E, Mix M, Nestle U, Schimek-Jasch T, Wiehle R, Mader I, Würtemberger U, Langen KJ, Niyazi M, Paulsen F, König L, Giordano FA, Spehl I, Bernhardt D, Schymalla MM, Pöttgen C, Semrau S, Brunner T, Hültenschmidt B, Krause BJ, Ciernik IF, Beck J, Baumert BG, Meyer PT, Urbach H, Popp I; GLIAA Study Group.
O-(2-[¹⁸F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial.
Lancet Oncol. 2025 Dec 19:S1470-2045(25)00642-4. doi: 10.1016/S1470-2045(25)00642-4. PMID: 41429128. Interventional study. ˍ